Bansal N, Mims J, Kuremsky JG, Olex AL, Zhao W, Yin L, Wani R, Qian J, Center B, Marrs GS, Porosnicu M, Fetrow JS, Tsang AW, Furdui CM. Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer
. Antioxid Redox Signal. 2014;21(2):221-236.
Garg S, Kilburn JM, Randolph DM, Lucas JT, Urbanic JJ, Porosnicu M, Hinson WH, Kearns WT, Greven KM. Re-irradiation for second primary or recurrent cancers of the head and neck: composite dosimetric measures to evaluate dose to the carotid arteries [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S480-S481.
Porosnicu M, Liu J, Lyles D. Susceptibility of head and neck cancer to an attenuated model of the oncolytic vesicular stomatitis virus expressing suicide genes [abstract]. J Clin Oncol. 2010;27(15 Suppl):e14604.
Blackstock A, Petty J, Oaks T, Porosnicu M, Clark H, Lovato J, Miller A. Gefitinig (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. J Clin Oncol. 2007;25(18 Suppl):Abstr18165.
Blackstock AW, Jensen CA, Petty WJ, Oaks T, Porosnicu M, Clark H, Lovato JF, Miller A. Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S476.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."